Common Sense Oncology: outcomes that matter
- PMID: 37467768
- DOI: 10.1016/S1470-2045(23)00319-4
Common Sense Oncology: outcomes that matter
Conflict of interest statement
AG reports consulting fees from Seattle Genetics and speaking honoraria from Curio. BW reports research funding from Bristol Myers Squibb, Ontario Institute of Cancer Research, Queen's University, National Breast Cancer Foundation of Australia, and the Kidney Cancer Research Network of Canada; and honoraria from AstraZeneca. WvdG reports institutional research grants from Eli Lilly, Boehringer Ingelheim, and SpringworksTx; and institutional consulting fees from SpringworksTx, PTC Therapeutics, and Agenus. ES-P-d-C reports speaking honoraria from Lactrealis and is on the Board of Directors of the American Society of Clinical Oncology. SS reports travel support from Queen's University. FYM reports consulting fees from Cancer em foco, AstraZeneca, and IASLC. BLM reports speaking honoraria from Servier Pharmaceuticals. SB reports honoraria for advisory boards from Taiho, Astellas, Merck, and Amgen. DG reports consulting fees from Vivio Health; stock ownership in TailorMed and Vivio Health; and serves as Board Member of Optimal Cancer Care Alliance. BG reports consulting fees from Vivio Health. KH reports research support from Pfizer. DK reports speaking honoraria from Amgen and MSD. KK reports consulting fees from Vivio Health and stock ownership in Vivio Health and Cadex Genomics. DC is the Editor-in-Chief of The Lancet Oncology. All other authors declare no competing interests. The opinions expressed by the authors are their own and this material should not be interpreted as representing the official viewpoint of the US Department of Health and Human Services, the National Institutes of Health, or the National Cancer Institute. The CSO organising committee gratefully acknowledges Robert J Shillman PhD (Doctor Bob) for his support of the initial planning meeting in April, 2023.
Comment in
-
Common Sense Oncology: including everyone.Lancet Oncol. 2023 Oct;24(10):e403. doi: 10.1016/S1470-2045(23)00359-5. Lancet Oncol. 2023. PMID: 37797641 No abstract available.
MeSH terms
LinkOut - more resources
Full Text Sources
